- $58.75m
- $37.87m
- $48.47m
Brief: Gossamer Bio Q3 EPS USD -0.14
Gossamer Bio Inc expected to post a loss of 15 cents a share - Earnings Preview
Gossamer Bio Inc reports results for the quarter ended in June - Earnings Summary
Brief: Gossamer Bio Q2 EPS USD 0.22
Gossamer Bio Inc expected to post earnings of 23 cents a share - Earnings Preview
Gossamer Bio gains after rival Aerovate scraps late-stage trial of lead drug
Brief: Gossamer Bio To Provide Updated Seralutinib TORREY Open-Label Extension Data At The American Thoracic Society 2024 International Conference
Gossamer Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Gossamer Bio Q1 EPS USD -0.19
U.S. RESEARCH ROUNDUP- ServiceNow, Ulta Beauty, Vertex Pharmaceuticals
Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition (updated)
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment
Brief: Gossamer Bio And Chiesi Group Announce Transformative Global Collaboration To Develop And Commercialize Seralutinib In PAH, PH-ILD & Other Indications
Gossamer Bio Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Gossamer Bio Announces Appointment Of Steven D. Nathan, M.D., And Skye Drynan To Its Board Of Directors
Brief: Gossamer Bio Q4 EPS USD -0.21
Gossamer Bio Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Gossamer Bio Inc On October 19, Got Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Gossamer Bio Director Kristina Burow Resigns, Size Of Board Was Reduced From Six To Five Directors